Cory L Ahonen

age ~52

from Plainfield, NH

Get Report

Connected to:

Cory Ahonen Phones & Addresses

341 Bean Rd, Plainfield, NH 03781 • 6036327769
121 Anderson Hill Rd, Enfield, NH 03748
73 Lebanon St, Hanover, NH 03755
1600 Grand Ave, Saint Paul, MN 55105 • 6512289174
160 Grand Ave, Saint Paul, MN 55102
661 Ashland Ave, Saint Paul, MN 55104 • 6512929080
208 Western Ave N, Saint Paul, MN 55102 • 6512289174
4 Conestoga St, Wrenshall, MN 55797

Work

Company:

Adimab, llc
Jul 2019
Position:

Senior scientist i

Education

School / High School:

Dartmouth College
Jan 1, 2000 to Dec 31, 2003

Skills

Protein Expression • Molecular Biology • Pcr • Protein Purification • Biotechnology • Assay Development • Purification • Genomics • Flow Cytometry • Biochemistry • Qpcr • Lifesciences • Mutagenesis • Tissue Culture • Laboratory • Cell Biology • Cell Culture • Western Blotting • Fplc • Rt Pcr • Protein Chemistry • Molecular Cloning • Immunology • Genetics • Sds Page • Science • Cancer • Fermentation • Elisa • Dna • In Vitro • Microscopy • Gel Electrophoresis • Microbiology • Animal Models • Fluorescence Microscopy • Cell • Vaccines • In Vivo • Life Sciences • Enzyme Assays

Industries

Research

Resumes

Senior Scientist I

view source

Location:

341 Bean Rd, Plainfield, NH 03781

Industry:

Research

Work:

Adimab, Llc
Senior Scientist I
Adimab, Llc
Scientist Ii
Adimab, Llc Feb 2015 - Jul 2017
Scientist I
Mascoma Llc Mar 1, 2011 - Feb 2015
Research Assistant Iii
Dartmouth College Nov 1998 - Mar 2011
Research Associate

Education:

Dartmouth College Jan 1, 2000 - Dec 31, 2003
Macalester College Jan 1, 1990 - Dec 31, 1994
Bachelors, Bachelor of Science, Chemistry, Neuroscience

Skills:

Protein Expression
Molecular Biology
Pcr
Protein Purification
Biotechnology
Assay Development
Purification
Genomics
Flow Cytometry
Biochemistry
Qpcr
Lifesciences
Mutagenesis
Tissue Culture
Laboratory
Cell Biology
Cell Culture
Western Blotting
Fplc
Rt Pcr
Protein Chemistry
Molecular Cloning
Immunology
Genetics
Sds Page
Science
Cancer
Fermentation
Elisa
Dna
In Vitro
Microscopy
Gel Electrophoresis
Microbiology
Animal Models
Fluorescence Microscopy
Cell
Vaccines
In Vivo
Life Sciences
Enzyme Assays

Us Patents

Immunostimulatory Combinations
view source
US Patent:

7387271, Jun 17, 2008
Filed:

Dec 30, 2003
Appl. No.:

10/748010
Inventors:

Randolph J. Noelle - Plainfield NH, US
Cory L. Ahonen - Hanover NH, US
Ross M. Kedl - Roseville MN, US
Assignee:

3M Innovative Properties Company - St. Paul MN
Trustees of Dartmouth College - Hanover NH
International Classification:

A61K 39/12
A61K 39/02
A61K 38/19
A61K 39/395
A61K 31/44
A61K 31/435
A61K 31/47
C07K 14/715
US Classification:

2422781, 4241441, 4241841, 4242041, 4242341, 4242651, 4242771, 514 2, 514 44, 514311, 514315
Abstract:

The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

Ex Vivo Uses Of Immunostimulatory Combinations
view source
US Patent:

8329197, Dec 11, 2012
Filed:

Jul 29, 2010
Appl. No.:

12/845888
Inventors:

Randolph J. Noelle - Plainfield NH, US
Cory L. Ahonen - Hanover NH, US
Ross M. Kedl - Roseville MN, US
Assignee:

3M Innovative Properties Company - St. Paul MN
Trustees of Dartmouth - Hanover NH
International Classification:

A61K 39/00
A61K 39/395
A61K 31/44
A61K 31/47
A61K 38/19
C07K 14/725
US Classification:

4242781, 4241441, 4241841, 514 44 R, 514311, 514315, 514 11, 514 24, 514 37
Abstract:

The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

Tlr9 Agonist And Cd40 Agonist Immunostimulatory Combinations
view source
US Patent:

7993659, Aug 9, 2011
Filed:

Mar 17, 2008
Appl. No.:

12/049874
Inventors:

Randolph J. Noelle - Plainfield NH, US
Cory L. Ahonen - Hanover NH, US
Ross M. Kedl - Roseville MN, US
Assignee:

3M Innovative Properties Company - St. Paul MN
Trustees of Dartmouth College - Hanover NH
International Classification:

A61K 39/02
A61K 39/12
A61K 38/19
A61K 39/395
A61K 31/44
A61K 31/435
A61K 31/47
C12N 15/10
US Classification:

4242781, 4241441, 4241841, 4242041, 4242341, 4242651, 4242741, 4242771, 514311, 514315, 514 44 R
Abstract:

The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.

Maturation Of Dendritic Cells With Immune Response Modifying Compounds
view source
US Patent:

20030186440, Oct 2, 2003
Filed:

Jan 30, 2003
Appl. No.:

10/354767
Inventors:

Mark Tomai - Oakdale MN, US
John Vasilakos - Woodbury MN, US
Cory Ahonen - Hanover NH, US
Assignee:

3M Innovative Properties Company
International Classification:

A61K045/00
A61K031/4745
C12N005/08
US Classification:

435/377000, 435/372000, 424/093700, 514/292000
Abstract:

A method of inducing the maturation of dendritic cells by stimulating immature dendritic cells with an imidazoquinoline type immune response modifying compound. Dendritic cells that have been matured in this manner display increased antigen presenting ability and may be used as immunotherapeutic agents.

Method For Modulating Inflammatory Responses
view source
US Patent:

20080220006, Sep 11, 2008
Filed:

Nov 1, 2006
Appl. No.:

12/090369
Inventors:

Randolph J. Noelle - Plainfield NH, US
Li-Fan Lu - Seattle WA, US
Cory L. Ahonen - Enfield NH, US
International Classification:

A61K 39/00
A61P 37/02
US Classification:

4241841
Abstract:

The present invention is a method for inhibiting Tcell functional activities by blocking Tcell-mediated mast cell activation. It has been found IL-9 produced by Tcells activates mast cells, which in turn mediate an amplification loop critical for graft tolerance and immune responses to tumors. Thus, a method for enhancing an immune response to a vaccine, such as a cancer vaccine, is also provided as is a method for increasing cell and humoral immunity in a subject.

Adjuvant Combinations Of Nkt Activator, Cd40 Agonist, And Optional Antigen, The Use Through Inducing Synergistic Cellular Immunity
view source
US Patent:

20100247537, Sep 30, 2010
Filed:

Apr 25, 2008
Appl. No.:

12/597615
Inventors:

Cory Ahonen - Enfield NH, US
Randolph Noelle - Plainfield NH, US
International Classification:

A61K 39/39
A61K 39/395
A61K 39/00
A61K 39/12
A61K 39/21
A61K 39/155
A61K 39/165
A61K 39/125
A61K 39/20
A61K 39/215
A61K 39/205
A61K 39/245
A61K 39/25
A61K 39/275
A61K 39/02
A61K 39/09
A61K 39/05
A61K 39/07
A61K 39/08
A61K 39/102
A61K 39/108
A61K 39/112
A61K 39/104
A61K 39/106
A61K 39/005
A61K 39/015
A61K 39/002
C12N 1/00
US Classification:

4241351, 4242741, 4241301, 4241331, 4241841, 4242041, 4242081, 4242111, 4242121, 4242161, 4242181, 4242191, 4242211, 4242241, 4242251, 4242291, 4242301, 4242321, 4242341, 4242441, 4242451, 4242461, 4242471, 4242551, 4242571, 4242581, 4242601, 4242611, 4242651, 4242691, 4242721, 4242731, 4242771, 4242831, 435243
Abstract:

Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.

Use Of Tlr Agonists And/Or Type 1 Interferons To Alleviate Toxicity Of Tnf-R Agonist Therapeutic Regimens
view source
US Patent:

20110182847, Jul 28, 2011
Filed:

Jun 16, 2008
Appl. No.:

12/664921
Inventors:

Randolph Noelle - Plainfield NH, US
Ross Kedl - Centennial CO, US
Cory Ahonen - Enfield NH, US
International Classification:

A61K 38/21
A61K 39/395
A61K 35/74
A61K 35/66
A61K 39/00
A61K 39/12
A61K 39/02
A61K 39/002
A61K 39/112
A61K 39/21
A61K 39/125
A61K 39/193
A61K 39/29
A61K 39/205
A61K 39/275
A61K 39/285
A61K 39/25
A61K 39/245
A61K 39/145
A61K 39/108
A61K 39/08
A61K 39/07
A61K 39/106
A61K 39/05
A61K 39/09
A61K 39/015
A61K 39/005
A61K 39/018
A61K 39/012
A61P 31/04
A61P 31/10
A61P 31/12
A61P 31/14
A61P 31/16
A61P 31/18
A61P 31/20
A61P 31/22
A61P 33/00
A61P 33/02
A61P 33/06
A61P 33/10
A61P 37/04
US Classification:

424 851, 4241301, 424780, 42419516, 4241841, 4242041, 4242341, 4242651, 4242741, 4242581, 4242081, 4242291, 4242161, 4242181, 4242251, 4242241, 4242321, 4242301, 4242091, 4242571, 4242601, 4242471, 4242461, 4242611, 4242451, 4242441, 4242721, 4242691, 4242701, 4242731, 4242771
Abstract:

Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/r TLR agonist).

Immunostimulatory Combinations
view source
US Patent:

20110280903, Nov 17, 2011
Filed:

Jun 22, 2011
Appl. No.:

13/165916
Inventors:

Randolph J. Noelle - Plainfield NH, US
Cory L. Ahonen - Hanover NH, US
Ross M. Kedi - Roseville MN, US
International Classification:

A61K 39/00
A61K 39/02
A61P 31/04
A61P 37/04
A61P 33/00
A61P 31/12
A61P 35/00
A61K 39/12
A61P 31/10
US Classification:

4241931, 4241841, 4242041, 4242341, 4242741, 4242651, 4242771
Abstract:

The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen.